Supremes to hear pay-for-delay Monday; EU backs Gilead's Quad;

@FiercePharma: Vietnam drug spending makes it a prime pharma target. Article | Follow @FiercePharma

@EricPFierce: Inspection report details why Hospira's hopes were recently dashed by the FDA. Story | Follow @EricPFierce

> The Supreme Court Monday will finally hear arguments over the so-called pay-for-delay deals between branded and generic drugmakers. Story

> European regulators are recommending approval of Gilead Science's ($GILD) 4-in-in HIV treatment, Stribild, a.k.a. the Quad. Item

> Some analysts think the wrinkle treatment drug Johnson & Johnson ($JNJ) is developing may finally give Allergan's ($AGN) Botox a run for its money. Story

> The European Medicines Agency is recommending restrictions on Otsuka's drug Pletal, prescribed for limping, because of concerns over side effects from cilostazol. Item

Medical Device News

 @FierceMedDev: If you missed our special report yesterday: Med Tech's 2012 R&D big spenders. More | Follow @FierceMedDev

 @MarkHFierce: Big win for GE - expanded FDA approval for an imaging agent, now to gauge risk of death in heart failure patients. Release | Follow @MarkHFierce

 @DamianFierce: Feds: The worry about device tax/regulatory slowdown for mobile apps is mostly hot air. More | Follow @DamianFierce

> 'Symbolic' device tax repeal vote passes in U.S. Senate. More

> Swiss team envisions cheap, durable Dx imaging for Africa. Article

> Study: Asuragen's molecular Dx better at Fragile X detection. Story

Biotech News

 @FierceBiotech: Cerulean Pharma's lead nanodrug crashes in lung cancer study. News | Follow @FierceBiotech

@JohnCFierce: No decision yet, but Soriot at AstraZeneca certainly sounds like he's going to do a biosimilars move. More | Follow @JohnCFierce

@RyanMFierce: No surprises here. BG-12 gets nod from EMA committee as first-line MS therapy. Release | Follow @RyanMFierce

> Titan claims victory for anti-addiction drug after mixed FDA panel votes. Report

> Genzyme boasts of durable response to MS drug Lemtrada. Story

> Report: CRO with a scandal-plagued past shuts down, leaving patients stranded. Article

And Finally... After AstraZeneca ($AZN) announced two rounds of job cuts totaling 5,050 employees, Bernstein Research analyst Tim Anderson told investors to that the company's solutions seemed reasonable but to expect "a long, slow crawl out from beneath a host of past problems." Item